Robert M Califf

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010
    Robert M Califf
    Duke Translational Medicine Institute, 200 Trent Dr, 1117 Davison Bldg, Durham, NC 27710, USA
    JAMA 307:1838-47. 2012
  2. doi request reprint The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment
    Robert M Califf
    Duke Translational Medicine Institute, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 17:782-6. 2008
  3. doi request reprint Linking scientific discovery and better health for the nation: the first three years of the NIH's Clinical and Translational Science Awards
    Robert M Califf
    Duke Translational Medicine Institute, Durham, North Carolina 27710, USA
    Acad Med 85:457-62. 2010
  4. ncbi request reprint Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Arch Intern Med 166:2027-34. 2006
  5. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
  6. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
  7. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
  8. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
  9. ncbi request reprint Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
  10. doi request reprint Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 102:1427-32. 2008

Collaborators

Detail Information

Publications141 found, 100 shown here

  1. doi request reprint Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010
    Robert M Califf
    Duke Translational Medicine Institute, 200 Trent Dr, 1117 Davison Bldg, Durham, NC 27710, USA
    JAMA 307:1838-47. 2012
    ..Strengthened reporting requirements for studies registered with ClinicalTrials.gov enable a comprehensive evaluation of the national trials portfolio...
  2. doi request reprint The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment
    Robert M Califf
    Duke Translational Medicine Institute, Durham, NC 27715, USA
    Pharmacoepidemiol Drug Saf 17:782-6. 2008
  3. doi request reprint Linking scientific discovery and better health for the nation: the first three years of the NIH's Clinical and Translational Science Awards
    Robert M Califf
    Duke Translational Medicine Institute, Durham, North Carolina 27710, USA
    Acad Med 85:457-62. 2010
    ....
  4. ncbi request reprint Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Arch Intern Med 166:2027-34. 2006
    ..We sought to determine recent trends in adherence to guideline-based therapies for NSTE ACS...
  5. doi request reprint Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease
    Svati H Shah
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 163:844-850.e1. 2012
    ..Cardiovascular risk models remain incomplete. Small-molecule metabolites may reflect underlying disease and, as such, serve as novel biomarkers of cardiovascular risk...
  6. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
    ..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
  7. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
  8. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  9. ncbi request reprint Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
    ..Recent data suggest that differences in response to therapy and survival exist between African Americans and Caucasians with heart failure. Whether these differences exist in acute decompensated heart failure (ADHF) is uncertain...
  10. doi request reprint Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 102:1427-32. 2008
    ..Unfortunately, beta blockers were underused acutely in patients with sustained VT/VF...
  11. pmc A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment
    Lynda A Szczech
    Renal Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Kidney Int 77:239-46. 2010
    ..These differential outcomes underscore the need for dedicated trials in these subpopulations...
  12. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  13. doi request reprint Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Ann Intern Med 158:861-8. 2013
    ....
  14. ncbi request reprint Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  15. ncbi request reprint Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Interv Cardiol 20:299-306. 2007
    ..Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear...
  16. ncbi request reprint Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy
    Trip J Meine
    Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
    Am Heart J 149:670-4. 2005
    ..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy...
  17. doi request reprint Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 156:185-92. 2008
    ....
  18. pmc Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
    Circulation 125:749-56. 2012
    ..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes...
  19. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  20. doi request reprint Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
    Mark Y Chan
    Duke Clinical Research Institute, Durham, North Carolina, USA
    JACC Cardiovasc Interv 1:369-78. 2008
    ..We sought to characterize the utilization and impact of a conservative medical management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and significant coronary artery disease on early angiography...
  21. doi request reprint Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)
    Robert M Califf
    Duke Translational Medicine Institute, Durham, North Carolina, USA
    Am J Cardiol 104:151-7. 2009
    ..In conclusion, no evidence was found of adverse interactions between the angiotensin-receptor blocker valsartan and beta blockers or of a negative effect of the combination of valsartan, captopril, and beta blockers...
  22. doi request reprint Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study
    Yee Weng Wong
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Heart Fail 6:203-10. 2013
    ..However, predictors associated with the increased risk of incident HF have not been well characterized. We aimed to identify independent predictors of incident HF hospitalization among patients with impaired glucose tolerance...
  23. ncbi request reprint Relationship between depressive symptoms and long-term mortality in patients with heart failure
    Wei Jiang
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 154:102-8. 2007
    ..The study sought to assess the association of depressive symptoms and long-term mortality of patients with HF and to explore the prognostic predictability of the Beck Depression Inventory (BDI) scale for patients with HF...
  24. doi request reprint Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Eur Heart J 31:211-21. 2010
    ..To determine whether predictors of sudden cardiac death (SCD) vary with time after myocardial infarction (MI)...
  25. ncbi request reprint Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC, USA
    Am J Med 119:70.e1-8. 2006
    ..Accordingly, the current study examines the relationship of African American race to patient-related clinical factors, angiographic findings, and clinical events...
  26. ncbi request reprint Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft
    Rajendra H Mehta
    Division of Cardiology, Department of Internal Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Circulation 114:I396-401. 2006
    ..The influence of an internal mammary artery (IMA) graft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unknown...
  27. doi request reprint Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Circulation 124:280-8. 2011
    ....
  28. doi request reprint Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:448-58. 2011
    ..We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials...
  29. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
    ..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
  30. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  31. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009
    ....
  32. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  33. doi request reprint Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
    Jonathan P Piccini
    Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27710, USA
    Circulation 127:224-32. 2013
    ..We sought to define the factors associated with the occurrence of stroke and systemic embolism in a large, international atrial fibrillation (AF) trial...
  34. pmc Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 164:379-386.e1. 2012
    ..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes...
  35. ncbi request reprint Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
    Hassan Kassem-Moussa
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:439-46. 2004
    ..Stroke is a rare but serious event that complicates the course of patients with acute coronary syndromes (ACS). The type, outcome, and risk factors of stroke occurring in stabilized patients with ACS have not been previously reported...
  36. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  37. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  38. ncbi request reprint High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2594-600. 2005
    ....
  39. doi request reprint Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database
    John L Petersen
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 159:462-470.e1. 2010
    ..Relationships between long-term use and level of dual antiplatelet therapy and outcomes after drug-eluting stent implantation are not well established...
  40. ncbi request reprint Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy
    Gillian D Sanders
    Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
    Am Heart J 153:951-9. 2007
    ....
  41. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  42. doi request reprint Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?
    Melissa H Kong
    Duke Clinical Research Institute, Durham, NC, USA
    Ann Noninvasive Electrocardiol 15:209-17. 2010
    ..We aimed to determine whether patients with AF and heart failure with preserved ejection fraction (EF) survive longer with rhythm versus rate-control strategy...
  43. doi request reprint The impact of postrandomization crossover of therapy in acute coronary syndromes care
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:211-9. 2011
    ..Using SYNERGY as an example, we demonstrate the difficulty of evaluating the effect of postrandomization events in clinical trials and discuss possible methodology...
  44. doi request reprint Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:369-74. 2008
    ..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
  45. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  46. doi request reprint Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
    Renato D Lopes
    Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 311, Terrace Level, Durham, NC 27705, USA
    Eur Heart J 29:1827-33. 2008
    ..The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS...
  47. ncbi request reprint Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II
    Sana M Al-Khatib
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Ann Intern Med 142:593-600. 2005
    ..3 or less...
  48. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  49. doi request reprint Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 61:1998-2006. 2013
    ..This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban...
  50. doi request reprint Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 61:651-8. 2013
    ..The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care...
  51. doi request reprint Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin
    Michael P Thomas
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:114-9. 2012
    ..The required intensity of anticoagulation for benefit may be relatively modest when UFH is administered concomitantly with dual or triple platelet-directed therapy, particularly in patients undergoing early coronary revascularization...
  52. ncbi request reprint Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Durham, NC, USA
    Am Heart J 148:122-8. 2004
    ..We sought to compare resource use, costs, and health outcomes among patients taking prescribed therapy for heart failure and randomly assigned to receive valsartan or placebo...
  53. doi request reprint Antidepressant use, depression, and survival in patients with heart failure
    CHRISTOPHER M O'CONNOR
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt St, Box 3356, Durham, NC 27705, USA
    Arch Intern Med 168:2232-7. 2008
    ..Because depression has also been shown to be associated with increased mortality in these patients, it remains unclear if this association is attributable to the use of antidepressants or to depression...
  54. ncbi request reprint Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
    L Kristin Newby
    Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 113:203-12. 2006
    ..Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use...
  55. ncbi request reprint Statin use and sex-specific stroke outcomes in patients with vascular disease
    Cheryl D Bushnell
    Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
    Stroke 37:1427-31. 2006
    ..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
  56. ncbi request reprint Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation
    L Kristin Newby
    Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 16:119-28. 2003
    ..While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically...
  57. ncbi request reprint Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
    Abdallah G Rebeiz
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Med 116:119-29. 2004
    ..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization...
  58. ncbi request reprint Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock
    Rajendra H Mehta
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:793-6. 2007
    ..This information may help physicians in deciding treatment options for patients with cardiogenic shock and counseling them about their risks...
  59. ncbi request reprint Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  60. doi request reprint Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Int J Cardiol 139:123-33. 2010
    ....
  61. doi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  62. doi request reprint Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
    J Thorac Cardiovasc Surg 136:1149-55. 2008
    ..Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery...
  63. ncbi request reprint Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
    Kenneth W Mahaffey
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
    Eur Heart J 28:425-32. 2007
    ..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery...
  64. ncbi request reprint The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 151:1205-13. 2006
    ..We characterized guideline adherence for NSTE ACS by risk status...
  65. ncbi request reprint The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA, and Greenlane Cardiovascular Service, Auckland City Hospital, New Zealand
    Eur Heart J 28:415-24. 2007
    ..However, the relative prognostic importance of these measures over other baseline variables is less known...
  66. ncbi request reprint Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
    John H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Med 115:613-9. 2003
    ..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...
  67. doi request reprint Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:884-892.e1. 2011
    ..Dose adjustment of renally excreted antithrombotic drugs is recommended for patients with reduced renal function. We examined the influence of dose modification on bleeding and efficacy...
  68. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  69. ncbi request reprint Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy
    Jeffrey S Berger
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 117:192-9. 2008
    ..We therefore compared the acute mortality and bleeding risks associated with the initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients...
  70. doi request reprint Long-term clinical outcomes following coronary stenting
    Kevin J Anstrom
    Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:1647-55. 2008
    ..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
  71. pmc Safety and transparency of pediatric drug trials
    Daniel K Benjamin
    Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Arch Pediatr Adolesc Med 163:1080-6. 2009
    ....
  72. doi request reprint Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
    Tracy Y Wang
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Circulation 123:722-30. 2011
    ..This analysis examines efficacy and safety of early eptifibatide in the setting of concurrent upstream clopidogrel use...
  73. pmc Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score
    CHRISTOPHER M O'CONNOR
    Duke Clinical Research Institute, Duke University Medical Center, 2400 North Pratt Street, Box 3356, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 55:872-8. 2010
    ..Identifying high-risk heart failure (HF) patients at hospital discharge may allow more effective triage to management strategies...
  74. doi request reprint Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease
    Svati H Shah
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 160:371-379.e2. 2010
    ..Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification...
  75. doi request reprint Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease
    Aslan T Turer
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    J Thorac Cardiovasc Surg 137:1468-74. 2009
    ..We examined the effect of body mass index on the association between revascularization strategy and survival in patients with coronary artery disease...
  76. ncbi request reprint Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
    ..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure...
  77. doi request reprint Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 158:792-8. 2009
    ..Current practice related to the management of atrial fibrillation (AF) complicating coronary artery bypass grafting (CABG) is uncertain...
  78. ncbi request reprint Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
    Robert M Califf
    Duke Transitional Medicine Institute, Durham, NC 27715, USA
    Am Heart J 156:623-32. 2008
    ..The study was designed to evaluate whether reducing postprandial hyperglycemia, blockade of the renin-angiotensin-aldosterone system, or both interventions reduce the risk of T2DM or cardiovascular events in patients with IGT...
  79. ncbi request reprint Outcomes of second revascularization procedures after stent implantation
    Richard P Konstance
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Med Syst 32:177-86. 2008
    ..Further studies are needed to determine the optimum application for CABG vs. DES as a second or third revascularization procedure...
  80. doi request reprint Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 365:883-91. 2011
    ..Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin...
  81. doi request reprint Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 103:76-81. 2009
    ..e., death and/or rehospitalization) in patients with HF in the design of treatment strategies for novel therapeutic agents in randomized controlled clinical trials...
  82. doi request reprint Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 57:138-46. 2011
    ..The purpose of this study was to examine the association between lower socioeconomic status (SES), as ascertained by years of education, and outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI)...
  83. doi request reprint Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
    Adrian F Hernandez
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 157:271-7. 2009
    ..However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality...
  84. doi request reprint Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
    Kent R Nilsson
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Heart 96:838-42. 2010
    ..This study compared a rate control strategy to an anti-arrhythmic-based rhythm control strategy for the treatment of AF following myocardial infarction...
  85. doi request reprint Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Box 17969, Durham, NC 27715, USA
    Eur Heart J 29:880-7. 2008
    ....
  86. ncbi request reprint Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  87. ncbi request reprint Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Circulation 105:322-7. 2002
    ..90 [95% CI, 0.67 to 1.20]) and in patients without a history of CABG (unadjusted HR, 0.89 [95% CI, 0.80 to 0.99])...
  88. ncbi request reprint Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin
    Arno Breeman
    Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cardiology 98:195-201. 2002
    ..e. medical treatment, percutaneous coronary intervention (PCI) (balloon), PCI (stent), or coronary artery bypass grafting (CABG)...
  89. ncbi request reprint Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada
    Wayne B Batchelor
    Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, FL, USA
    Am Heart J 145:349-55. 2003
    ....
  90. ncbi request reprint Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1251-60. 2003
    ..The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI)...
  91. ncbi request reprint Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
    Eric J Topol
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:399-406. 2003
    ....
  92. ncbi request reprint Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  93. ncbi request reprint Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  94. ncbi request reprint Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial
    Hitinder S Gurm
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 43:542-8. 2004
    ....
  95. ncbi request reprint International differences in evolution of early discharge after acute myocardial infarction
    Padma Kaul
    University of Alberta, Edmonton, Alberta, Canada
    Lancet 363:511-7. 2004
    ..We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge...
  96. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  97. ncbi request reprint Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT
    Wei Ching Chang
    University of Alberta, Edmonton, Alberta, Canada
    Am Heart J 148:62-71. 2004
    ..The objective of the current study was to develop an approach to predicting outcome in NSTE-ACS that could account for the changing nature of risk...
  98. ncbi request reprint Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial
    Marino Labinaz
    University of Ottawa Heart Institute, Ottawa, Ontario
    Can J Cardiol 20:773-8. 2004
    ..For patients with ACS undergoing percutaneous balloon angioplasty without coronary stenting in the era of platelet glycoprotein IIb/IIIa blockade, the long-term prognosis is less clear...
  99. ncbi request reprint Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
    Debabrata Mukherjee
    University of Michigan Health System, Ann Arbor, Mich, USA
    Am Heart J 144:995-1002. 2002
    ..Minimal data are available on LMWH combined with platelet glycoprotein (GP) IIb/IIIa inhibitors...
  100. ncbi request reprint Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 288:2130-5. 2002
    ..Rates of nonfatal ischemic complications were significantly diminished...